MALIN CORP PLC (MLC.I) Stock Price, Forecast & Analysis
Europe - Euronext Dublin - DUB:MLC - IE00BVGC3741 - Common Stock
MLC.I Key Statistics, Chart & Performance
The current stock price of MLC.I is 8 EUR. In the past month the price increased by 0.63%. In the past year, price increased by 36.75%.
MLC.I Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 49.58 | 20.80B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 49.88 | 20.93B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 56.84 | 19.41B | ||
| SRT.DE | SARTORIUS AG | 43.97 | 15.01B | ||
| QIA.DE | QIAGEN N.V. | 19.96 | 8.78B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 16.07 | 2.35B | ||
| EVT.DE | EVOTEC SE | N/A | 2.32B | ||
| GXI.DE | GERRESHEIMER AG | 7.45 | 949.16M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.79 | 211.78M | ||
| 1SRT.MI | SARTORIUS AG | N/A | 7.02B |
Related stock screener links
About MLC.I
Company Profile
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 2 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, WaveBreak, KNOW Bio, and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. KNOW Bio is a life science company engaged in the fields of nitric oxide and precision light therapy. WaveBreak Therapeutics company focuses on the development of medicines for the treatment of protein-misfolding diseases including Alzheimer's and Parkinson's. Artizan is a biotechnology company.
Company Info
MALIN CORP PLC
The Lennox Building, 50 Richmond Street South
DUBLIN DUBLIN IE
Employees: 2
Phone: 353019053531
MALIN CORP PLC / MLC.I FAQ
What does MALIN CORP PLC do?
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 2 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, WaveBreak, KNOW Bio, and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. KNOW Bio is a life science company engaged in the fields of nitric oxide and precision light therapy. WaveBreak Therapeutics company focuses on the development of medicines for the treatment of protein-misfolding diseases including Alzheimer's and Parkinson's. Artizan is a biotechnology company.
What is the stock price of MALIN CORP PLC today?
The current stock price of MLC.I is 8 EUR. The price increased by 3.9% in the last trading session.
Does MLC stock pay dividends?
MLC.I does not pay a dividend.
What is the ChartMill technical and fundamental rating of MLC stock?
MLC.I has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is MLC.I stock listed?
MLC.I stock is listed on the Euronext Dublin exchange.
What is the ownership structure of MALIN CORP PLC (MLC.I)?
You can find the ownership structure of MALIN CORP PLC (MLC.I) on the Ownership tab.
MLC.I Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLC.I. When comparing the yearly performance of all stocks, MLC.I turns out to be only a medium performer in the overall market: it outperformed 69.25% of all stocks.
MLC.I Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MLC.I Forecast & Estimates
5 analysts have analysed MLC.I and the average price target is 15.81 EUR. This implies a price increase of 97.63% is expected in the next year compared to the current price of 8.